SEC Comment Letter for Tvardi Therapeutics, (TVRD) — Jun 5, 2025
Tvardi Therapeutics, Inc.
Date: June 5, 2025 · CIK: 0001346830 · Accession: 0000000000-25-005973
AI Filing Summary & Sentiment
File numbers found in text: 333-287675
Letter
June 5, 2025 Imran Alibhai, Ph.D. Chief Executive Officer Tvardi Therapeutics, Inc. 3 Sugar Creek Ctr. Blvd. Suite 525 Sugar Land, TX 77478 Re:Tvardi Therapeutics, Inc. Registration Statement on Form S-1 Filed May 30, 2025 File No. 333-287675 Dear Imran Alibhai Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Divakar Gupta, Esq.
Show Raw Text
June 5, 2025
Imran Alibhai, Ph.D.
Chief Executive Officer
Tvardi Therapeutics, Inc.
3 Sugar Creek Ctr. Blvd.
Suite 525
Sugar Land, TX 77478
Re:Tvardi Therapeutics, Inc.
Registration Statement on Form S-1
Filed May 30, 2025
File No. 333-287675
Dear Imran Alibhai Ph.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Divakar Gupta, Esq.